Exhibit 99.1 Vir Biotechnology Provides Corporate Update and Reports First Quarter 2026 Financial Results – Global strategic collaboration with Astellas to advance PSMA-targeted, PRO-XTEN dual-masked T-cell engager (TCE) VIR-5500 closed and first patient dosed in Phase 1 dose-expansion cohorts in patients with late-line metastatic prostate cancer ® – Company will present complete Week 96 Phase 2 SOLSTICE data on its combination regimen for chronic hepatitis delta (CHD) at the European Association for the St ...